November 14, 2019
Mochida Pharmaceutical’s biosimilar version of Forteo (teriparatide) and Kyowa Pharmaceutical Industry’s Enbrel (etanercept) follow-on will be available for self-injection as a key reimbursement panel approved on November 13 their addition to a list of products covered by related physician fees...read more